<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01071642</url>
  </required_header>
  <id_info>
    <org_study_id>sor495209ctil</org_study_id>
    <nct_id>NCT01071642</nct_id>
  </id_info>
  <brief_title>The Influence of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Renal Function in Patients Undergoing Non-emergent Coronary Angiography</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Soroka University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Soroka University Medical Center</source>
  <brief_summary>
    <textblock>
      The aim of the current study is to evaluate prospectively whether concomitant administration
      of RAAS blockers (namely ACE-I and ARBs') influence the change in estimated GFR (eGFR) after
      administration of contrast media in patients undergoing non-emergent coronary angiography.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in eGFR from baseline to 48 hours following the exposure to the contrast.</measure>
    <time_frame>48 hours after exposure to the contrast</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>1. Rate of eGFR decrease&gt;25% from the baseline, 2. Length of hospitalization,</measure>
    <time_frame>48-72 hours after exposure to contrast</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Blood Pressure</condition>
  <arm_group>
    <arm_group_label>continue ace-i and arb's versus dicontinue</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>group b</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>group c</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>stop ace-i/arb 24 h before procedure and restarted 24 hours after the procedure</intervention_name>
    <description>ACE/ARB stopped 24 hours prior to the procedure and restarted 24 hours after the procedure</description>
    <arm_group_label>group b</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACE/ARB stopped 24 hours before procedure and start immediately after</intervention_name>
    <description>ACE/ARB stopped 24 hours prior to the procedure and restarted immediately after the procedure</description>
    <arm_group_label>group c</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Age&gt;18 years

          -  2. Subjects on chronic therapy with ACE-I and/or ARBs' (confirmed by electronic
             records in their medical file)

          -  3. Subjects planned to undergo non-emergent coronary angiography.

          -  4. Signed informed consent

        Exclusion Criteria:

          -  1. eGFR&lt;30 ml/min at baseline

          -  2. Chronic utilization of NSAIDS and Cox-2 selective inhibitors

          -  3. Chronic treatment with mineralocorticosteroid receptor blocker

          -  4. Systolic blood pressure&lt;90 mmHg

          -  5. Planned staged (repeated) procedure within 48 hours

          -  6. Administration of contrast within 14 days prior to the enrollment

          -  7. contraindication to stop ACE-I or ARB'S
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Talya Wolak</name>
      <address>
        <city>Bear Sheva</city>
        <zip>8410</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 18, 2010</study_first_submitted>
  <study_first_submitted_qc>February 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2010</study_first_posted>
  <last_update_submitted>June 20, 2017</last_update_submitted>
  <last_update_submitted_qc>June 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Soroka University Medical Center</investigator_affiliation>
    <investigator_full_name>Talya Wolak</investigator_full_name>
    <investigator_title>senior doctor internal medicine department</investigator_title>
  </responsible_party>
  <keyword>Change in eGFR from baseline to 72 hours following the exposure to the contrast.</keyword>
  <keyword>Rate of eGFR decrease&gt;25% from the baseline</keyword>
  <keyword>Length of hospitalization.</keyword>
  <keyword>Requirement of unplanned therapy for elevated blood pressure</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
    <mesh_term>Angiotensin Receptor Antagonists</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

